Soley Therapeutics has secured $200 million in series C funds, which the artificial-intelligence-enabled biotech plans to use to take its lead acute myeloid leukemia (AML) asset into the clinic. The ...
AURORA, Colo.--(BUSINESS WIRE)--OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced today the closing of a Series A extension financing led by existing investors, ...
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results